I'm LongbridgeAI, I can summarize articles.Amgen Inc. (AMGN) stock rose 1.32% to $423.64, outperforming competitors like Johnson & Johnson and Pfizer during a broader market decline on Tuesday. This marks the third consecutive day of gains for Amgen. Trading volume exceeded its 50-day average, though the stock remains 5.23% below its 52-week high.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Amgen Inc. (AMGN) rose 1.32% to $423.64 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.17% to 7,670.84 and Dow Jones Industrial Average falling 0.26% to 51,349.92.
This was the stock's third consecutive day of gains.
Amgen Inc. closed 5.23% below its 52-week high of $447.03, which the company achieved on August 25th.
The stock outperformed some of its competitors Tuesday, as Johnson & Johnson (JNJ) fell 1.61% to $267.57, Pfizer Inc. (PFE) remained unchanged, and AbbVie Inc. (ABBV) fell 1.12% to $263.29.
Trading volume (3.3 M) eclipsed its 50-day average volume of 2.8 M.
Data source: Dow Jones Market Data, FactSet. Data compiled September 29, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-29-26 1634ET